DK3768846T3 - Virale og ikke-virale nanoplasmidvektorer med forbedret produktion - Google Patents
Virale og ikke-virale nanoplasmidvektorer med forbedret produktion Download PDFInfo
- Publication number
- DK3768846T3 DK3768846T3 DK19715345.5T DK19715345T DK3768846T3 DK 3768846 T3 DK3768846 T3 DK 3768846T3 DK 19715345 T DK19715345 T DK 19715345T DK 3768846 T3 DK3768846 T3 DK 3768846T3
- Authority
- DK
- Denmark
- Prior art keywords
- viral
- enhanced production
- nanoplasmid vectors
- nanoplasmid
- vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/55—Vectors comprising a special origin of replication system from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862645892P | 2018-03-21 | 2018-03-21 | |
PCT/US2019/023209 WO2019183248A1 (en) | 2018-03-21 | 2019-03-20 | Viral and non-viral nanoplasmid vectors with improved production |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3768846T3 true DK3768846T3 (da) | 2023-07-24 |
Family
ID=66001381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19715345.5T DK3768846T3 (da) | 2018-03-21 | 2019-03-20 | Virale og ikke-virale nanoplasmidvektorer med forbedret produktion |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210010021A1 (lt) |
EP (2) | EP3768846B1 (lt) |
JP (1) | JP2021518150A (lt) |
KR (1) | KR20210016330A (lt) |
CN (1) | CN112154208A (lt) |
AU (1) | AU2019240068A1 (lt) |
CA (1) | CA3093346A1 (lt) |
DK (1) | DK3768846T3 (lt) |
ES (1) | ES2950736T3 (lt) |
FI (1) | FI3768846T3 (lt) |
LT (1) | LT3768846T (lt) |
SG (1) | SG11202009009UA (lt) |
WO (1) | WO2019183248A1 (lt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3151464A1 (en) | 2019-09-18 | 2021-03-25 | Bruce C. SCHNEPP | Synthetic dna vectors and methods of use |
US20230051406A1 (en) | 2020-11-13 | 2023-02-16 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
AU2022299552A1 (en) | 2021-06-25 | 2024-01-04 | Oxford Biomedica (Us) Llc | Adeno-associated virus packaging systems |
WO2023014922A1 (en) | 2021-08-04 | 2023-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
CN114045305B (zh) * | 2021-10-15 | 2023-03-24 | 深圳市深研生物科技有限公司 | 多转座子系统 |
WO2023114901A2 (en) | 2021-12-15 | 2023-06-22 | Oxford Biomedica Solutions Llc | Methods and compositions for the production of adeno-associated virus |
WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
WO2024020320A2 (en) * | 2022-07-19 | 2024-01-25 | Rampart Bioscience, Inc. | Non-immunogenic circular, non-viral dna vectors |
CN117305339B (zh) * | 2023-11-30 | 2024-02-06 | 苏州左旋星生物科技有限公司 | 优化大肠杆菌基因编辑的载体及其应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04197185A (ja) * | 1990-11-28 | 1992-07-16 | Mitsui Toatsu Chem Inc | 酵母発現ベクター及びこれを用いた誘導的発現 |
GB9506051D0 (en) * | 1995-03-24 | 1995-05-10 | Univ Singapore | Gene expression |
US7279313B2 (en) | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2738842B1 (fr) | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
US5922583A (en) | 1995-10-17 | 1999-07-13 | Biostar Inc. | Methods for production of recombinant plasmids |
US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
JP2004267001A (ja) * | 2000-08-16 | 2004-09-30 | Kansai Tlo Kk | トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法 |
UY26317A1 (es) * | 2000-08-30 | 2000-10-31 | Alfonso Cayota Carlos Pritsch | Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo |
FR2821855B1 (fr) | 2001-03-09 | 2004-04-02 | Cayla | Genes synthetiques et plasmides bacteriens depourvus de cpg |
CA2794446C (en) * | 2001-04-04 | 2015-09-08 | Genencor International, Inc. | Uncoupled productive and catabolic host cell pathways |
WO2003091433A1 (fr) * | 2002-04-26 | 2003-11-06 | National Institute Of Advanced Industrial Science And Technology | Systeme d'expression pour molecule d'arn a tige-boucle ayant un effet d'arni |
WO2005003359A1 (ja) * | 2003-07-08 | 2005-01-13 | Japan Science And Technology Corporation | トランスジェニック生物を作製する方法およびシステム |
GB0327056D0 (en) | 2003-11-20 | 2003-12-24 | Cobra Biolog Ltd | Plasmid maintenance |
AU2005277510B2 (en) | 2004-08-19 | 2009-09-17 | Aldevron, L.L.C. | Process for plasmid DNA fermentation |
JP4804467B2 (ja) * | 2004-08-23 | 2011-11-02 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 多重rnaポリメラーゼiiiプロモーター発現構築物 |
TWI311152B (en) | 2004-09-17 | 2009-06-21 | Boehringer Ingelheim Rcv Gmbh & Co K | Host-vector system for antibiotic-free cole1 plasmid propagation |
WO2007004642A1 (ja) * | 2005-07-05 | 2007-01-11 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 改変トランスポゾンベクター及びその利用方法 |
WO2008153733A2 (en) | 2007-05-29 | 2008-12-18 | Nature Technology Corporation | Vectors and methods for genetic immunization |
AU2008286701B2 (en) * | 2007-08-14 | 2015-02-12 | Commonwealth Scientific And Industrial Research Organisation | Improved gene silencing methods |
US9045759B2 (en) | 2009-01-21 | 2015-06-02 | James Arthur Williams | DNA plasmids with improved copy number |
ES2679291T3 (es) * | 2011-12-07 | 2018-08-23 | Glenmark Pharmaceuticals S.A. | Casete de expresión |
AU2013309488A1 (en) | 2012-08-29 | 2015-03-05 | Nature Technology Corporation | DNA plasmids with improved expression |
WO2014077863A1 (en) * | 2012-11-19 | 2014-05-22 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
MX2015016755A (es) * | 2013-06-06 | 2016-04-13 | Novartis Ag | Reagrupamiento del virus de influenza. |
AU2016338565B2 (en) | 2015-10-14 | 2021-11-18 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
US20220042038A1 (en) * | 2018-12-20 | 2022-02-10 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
-
2019
- 2019-03-20 EP EP19715345.5A patent/EP3768846B1/en active Active
- 2019-03-20 ES ES19715345T patent/ES2950736T3/es active Active
- 2019-03-20 CA CA3093346A patent/CA3093346A1/en active Pending
- 2019-03-20 CN CN201980034026.9A patent/CN112154208A/zh active Pending
- 2019-03-20 KR KR1020207030139A patent/KR20210016330A/ko unknown
- 2019-03-20 FI FIEP19715345.5T patent/FI3768846T3/fi active
- 2019-03-20 DK DK19715345.5T patent/DK3768846T3/da active
- 2019-03-20 SG SG11202009009UA patent/SG11202009009UA/en unknown
- 2019-03-20 WO PCT/US2019/023209 patent/WO2019183248A1/en unknown
- 2019-03-20 JP JP2020551263A patent/JP2021518150A/ja active Pending
- 2019-03-20 EP EP22194460.6A patent/EP4151735A1/en active Pending
- 2019-03-20 AU AU2019240068A patent/AU2019240068A1/en active Pending
- 2019-03-20 LT LTEPPCT/US2019/023209T patent/LT3768846T/lt unknown
-
2020
- 2020-09-18 US US17/026,101 patent/US20210010021A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202009009UA (en) | 2020-10-29 |
EP3768846B1 (en) | 2023-06-21 |
JP2021518150A (ja) | 2021-08-02 |
ES2950736T3 (es) | 2023-10-13 |
LT3768846T (lt) | 2023-08-10 |
US20210010021A1 (en) | 2021-01-14 |
EP3768846A1 (en) | 2021-01-27 |
WO2019183248A1 (en) | 2019-09-26 |
FI3768846T3 (fi) | 2023-06-30 |
EP4151735A1 (en) | 2023-03-22 |
CA3093346A1 (en) | 2019-09-29 |
AU2019240068A1 (en) | 2020-10-01 |
KR20210016330A (ko) | 2021-02-15 |
CN112154208A (zh) | 2020-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3768846T3 (da) | Virale og ikke-virale nanoplasmidvektorer med forbedret produktion | |
DK3408382T3 (da) | Onkolytiske virale vektorer og anvendelser deraf | |
DK3507386T3 (da) | Fremgangsmåder og indretning, der øger effektiviteten af sekvensering med binding | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
IL271993A (en) | Viral vectors of cell lysis and their uses | |
DK3581190T3 (da) | Manipulerede naturlige dræberceller og anvendelser deraf | |
DK3612675T3 (da) | Mikrofibrilleret cellulose med forbedrede egenskaber og fremgangsmåder til fremstilling af samme | |
DK3872085T3 (da) | Stam-virussekvenser og anvendelser heraf | |
DK3434762T3 (da) | Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet | |
DK3268470T3 (da) | Transposasepolypeptider og anvendelser deraf | |
DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
DK3268024T3 (da) | Rekombinante glut1-adeno-associerede virusvektorkonstrukter og relaterede fremgangsmåder til genoprettelse af glut1-ekspression | |
DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf | |
DK3269809T3 (da) | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3397816T3 (da) | Undervandsplov og pløjning | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3692009T3 (da) | Biocementationsfremgangsmåde og system | |
DK3448419T3 (da) | Interferon-beta-antistoffer og anvendelser deraf | |
DK3743106T3 (da) | Influenzavirusvacciner og anvendelser deraf | |
DK3380496T3 (da) | Forbedret proteinproduktion og fremgangsmåder hertil | |
HK1253863A1 (zh) | 含prrsv次要蛋白的重組病毒載體及其製造方法與用途 | |
DK3291841T3 (da) | Onkolytisk hsv1-vektor og fremgangsmåder |